Platelet-rich emboli are associated with von Willebrand factor levels and have poorer revascularization outcomes.


Journal

Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 05 09 2019
revised: 18 10 2019
accepted: 20 10 2019
pubmed: 7 11 2019
medline: 29 9 2020
entrez: 6 11 2019
Statut: ppublish

Résumé

Platelets and von Willebrand factor (vWF) are key factors in thrombosis and thus are likely key components of acute ischemic stroke (AIS) emboli. We aimed to characterize platelet and vWF levels in AIS emboli and to assess associations between their expression levels and clinical and procedural information. Histopathological and immunohistochemical analysis of emboli collected as part of the multi-institutional RESTORE registry was performed. The composition of the emboli was quantified using Orbit Image Analysis machine learning software. Correlations between clot components and clinical and procedural information were assessed using the χ Ninety-one emboli samples retrieved from 63 patients were analyzed in the study. The mean platelet (CD42b) content of the clots was 33.9% and the mean vWF content of the clots was 29.8%. There was a positive correlation between platelet and vWF levels (ρ=0.564, p<0.001*, n=91). There was an inverse correlation between both platelets and vWF levels and percentage of red blood cells (RBCs) in the emboli (CD42b vs RBC: ρ=-0.535, p<0.001*, n=91; vWF vs RBC: ρ=-0.366, p<0.001*, n=91). Eighty-one percent of patients in the low platelet group had a good revascularization outcome (Thrombolysis in Cerebral Infarction 2c/3) compared with 58% in the high platelet group (χ Platelet and vWF levels in AIS emboli correlate with each other and both have an inverse relationship with RBC composition. Patients with platelet-rich clots have poorer revascularization outcomes.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Platelets and von Willebrand factor (vWF) are key factors in thrombosis and thus are likely key components of acute ischemic stroke (AIS) emboli. We aimed to characterize platelet and vWF levels in AIS emboli and to assess associations between their expression levels and clinical and procedural information.
MATERIALS AND METHOD METHODS
Histopathological and immunohistochemical analysis of emboli collected as part of the multi-institutional RESTORE registry was performed. The composition of the emboli was quantified using Orbit Image Analysis machine learning software. Correlations between clot components and clinical and procedural information were assessed using the χ
RESULTS RESULTS
Ninety-one emboli samples retrieved from 63 patients were analyzed in the study. The mean platelet (CD42b) content of the clots was 33.9% and the mean vWF content of the clots was 29.8%. There was a positive correlation between platelet and vWF levels (ρ=0.564, p<0.001*, n=91). There was an inverse correlation between both platelets and vWF levels and percentage of red blood cells (RBCs) in the emboli (CD42b vs RBC: ρ=-0.535, p<0.001*, n=91; vWF vs RBC: ρ=-0.366, p<0.001*, n=91). Eighty-one percent of patients in the low platelet group had a good revascularization outcome (Thrombolysis in Cerebral Infarction 2c/3) compared with 58% in the high platelet group (χ
CONCLUSION CONCLUSIONS
Platelet and vWF levels in AIS emboli correlate with each other and both have an inverse relationship with RBC composition. Patients with platelet-rich clots have poorer revascularization outcomes.

Identifiants

pubmed: 31685695
pii: neurintsurg-2019-015410
doi: 10.1136/neurintsurg-2019-015410
doi:

Substances chimiques

von Willebrand Factor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

557-562

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Andrew Douglas (A)

CÚRAM, SFI Research Centre for Medical Devices, National University of Ireland Galway, Galway, Ireland.

Seán Fitzgerald (S)

CÚRAM, SFI Research Centre for Medical Devices, National University of Ireland Galway, Galway, Ireland.
Department of Radiology, Mayo Clinic Rochester, Rochester, Minnesota, USA.

Oana Madalina Mereuta (OM)

CÚRAM, SFI Research Centre for Medical Devices, National University of Ireland Galway, Galway, Ireland.

Rosanna Rossi (R)

CÚRAM, SFI Research Centre for Medical Devices, National University of Ireland Galway, Galway, Ireland.

Sean O'Leary (S)

CÚRAM, SFI Research Centre for Medical Devices, National University of Ireland Galway, Galway, Ireland.

Abhay Pandit (A)

CÚRAM, SFI Research Centre for Medical Devices, National University of Ireland Galway, Galway, Ireland.

Ray McCarthy (R)

Galway Neuro Technology Centre, Cerenovus, Galway, Ireland.

Michael Gilvarry (M)

Galway Neuro Technology Centre, Cerenovus, Galway, Ireland.

Lukas Holmegaard (L)

Department of Radiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Margareta Abrahamsson (M)

Department of Radiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Mikael Jerndal (M)

Department of Radiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Niclas Dehlfors (N)

Department of Radiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Paul Brennan (P)

Interventional Neuroradiology Service, Department of Radiology, Beaumont Hospital, Dublin, Ireland.

Sarah Power (S)

Interventional Neuroradiology Service, Department of Radiology, Beaumont Hospital, Dublin, Ireland.

Alan O'Hare (A)

Interventional Neuroradiology Service, Department of Radiology, Beaumont Hospital, Dublin, Ireland.

Emma Griffin (E)

Interventional Neuroradiology Service, Department of Radiology, Beaumont Hospital, Dublin, Ireland.

David F Kallmes (DF)

Department of Radiology, Mayo Clinic Rochester, Rochester, Minnesota, USA.

Waleed Brinjikji (W)

Department of Radiology, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Department of Neurosurgery, Mayo Clinic Rochester, Rochester, Minnesota, USA.

István Szikora (I)

Department of Neurointerventions, National Institute of Neurosciences, Budapest, Hungary.

Turgut Tatlisumak (T)

Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, University of Gothenburg Sahlgrenska Academy, Gothenburg, Sweden.

Alexandros Rentzos (A)

Department of Radiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

John Thornton (J)

Interventional Neuroradiology Service, Department of Radiology, Beaumont Hospital, Dublin, Ireland.
Royal College of Surgeons in Ireland, Dublin, Ireland.

Karen Doyle (K)

CÚRAM, SFI Research Centre for Medical Devices, National University of Ireland Galway, Galway, Ireland karen.doyle@nuigalway.ie.
Department of Physiology, National University of Ireland Galway, Galway, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH